Medytox, Daewoong’s Botox Strain Dispute Set To Simmer Until Commission Decision

The ongoing battle between Korea's Medytox and Daewoong Pharm over the source of the botulinum toxin strain in Daewoong’s product looks set to rumble on until a trade commission unveils the results of its probe next year.

Gavel - chess — Who's Telling The Truth? Medytox, Daewoong Ping-Ponging Continues • Source: Shutterstock

After Daewoong Pharmaceutical Co. Ltd. recently announced the result of an analysis of the source spores in its botulinum toxin product, the South Korean pharma firm had expected this would end its long-running dispute with domestic neurotoxin manufacturer Medytox Inc.

But Medytox had not accepted the result, saying the appraisal was conducted under “highly unusual conditions” and meaning the spat...